Phase 2 N=80 VIVITROL as a Treatment for Cocaine and Alcohol Dependence
Cocaine Dependence · Alcohol Dependence
Primary: Urine Assay for Benzoylecgonine (BE), the Primary Metabolite of Cocaine. — 33.3; 31.7 Percentage of Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=62 NITI CAR27 (ColonRing) Compression Anastomosis in Colorectal Surgery
Colonic Neoplasms · Rectal Neoplasms · Diverticulitis
Primary: Anastomotic Leakage — 0 participants
Phase 3 N=126 Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults Aged 18 Years and Above
Human · Influenza
Primary: Percentage of Subjects With Seroconversion or Significant Increase in HI Titer Against Each of Three Vaccine Strains After One Vaccination of TIVf — 83; 60; 70; 48…
Phase 3 N=471 Stimulant Abuser Groups to Engage in 12-Step
Drug Abuse
Primary: Days of Stimulant Use — 2.35; 2.13 days of stimulant use — p=<0.05
Phase 1 N=29 Ultra-Low Dose Interleukin-2 for Refractory Chronic Graft Versus Host Disease
Graft Versus Host Disease
Primary: The Maximum Tolerated Dose and Toxicity Profile of an 8 Week Course of IL-2 in Patients With cGVHD and an Inadequate Response to Steroids. — 1 million IU/m2/day
Phase 4 N=978 Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure
Diabetes Mellitus, Type 2
Primary: Percentage of Patients Whose Glycosylated Haemoglobin (HbA1c) <7% at the End of the Comparative Period — 48.4; 45.9 percentage of participants — p=0.439
Phase 4 N=113 Low-Density Lipoprotein (LDL) Apheresis Using H.E.L.P. Therapy
Familial Hypercholesterolemia
Primary: Occurence of Death — 1; 1; 1; 1 participants
Phase 3 N=613 A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease
Alzheimer's Disease
Primary: Alzheimer's Disease Cooperative Study/Activities of Daily Living (ADCS/ADL) Inventory Change From Baseline — -1.72; -2.40; -2.78; -4.52 units on a scale — p=0.03
Phase 3 N=25,673 Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE
Cardiovascular Disease · Peripheral Arterial Disease · Diabetes Mellitus
Primary: Major Vascular Event — 1696; 1758 participants
Early Phase 1 N=30 Light for Renal Transplant Recipients Having a Sleep-Wake Dysregulation
Renal Disease · Sleep Disorders
Primary: Bedtime — 7.44; 7.24; 22.98; 22.48 Hours
Phase 3 N=351 CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b)
Lymphocytic Leukemia, Chronic
Primary: Progression-free Survival (PFS) — 16.5; 11.1 Months — p=<0.0001
Phase 4 N=800 A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH)
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Severity of Ocular Hyperemia in the Study Eye on a 5-Point Scale — 40; 49; 20; 71 Participants
Phase 3 N=602 Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy
Breast Neoplasms · Osteoporosis
Primary: Percent Change From Baseline in Lumbar Spine (L1-L4) Bone Mineral Density (BMD) — 1.955; -2.325 Percentage of BMD
Phase 3 N=744 A 24-week Study of Fluticasone Furoate/Vilanterol Inhalation Powder in Subjects of Asian Ancestry With COPD
Pulmonary Disease, Chronic Obstructive
Primary: Mean Change From Baseline in Clinic Visit Pre-dose Trough FEV1 at Day 169 — -0.027; 0.113; 0.152; 0.167 Liters — p=<0.001
Phase 2 N=12 Effect of Repetitive Transcranial Magnetic Stimulation on Language in Alzheimer's Disease
Alzheimer's Disease · Aphasia · Dementia
Primary: Cognitive Assessment Task Scores Before, During and After rTMS. — 26.9; 13.3; 17.0 units on a scale